Table 14.3.1  Treatment-Emergent Adverse Events
ONC-2024-001 | Safety Population (N=120)
MedDRA SOC	Preferred Term	Any grade, n (%)	Grade ≥ 3, n (%)	
ANY TEAE	-- Any preferred term --	117 (97.5)	65 (54.2)	
Gastrointestinal disorders	Nausea	52 (43.3)	14 (11.7)	
Gastrointestinal disorders	Diarrhoea	51 (42.5)	11 (9.2)	
Investigations	Alanine aminotransferase increased	42 (35.0)	8 (6.7)	
General disorders and administration site conditions	Fatigue	38 (31.7)	9 (7.5)	
Investigations	Blood creatine phosphokinase increased	33 (27.5)	9 (7.5)	
Investigations	Aspartate aminotransferase increased	31 (25.8)	6 (5.0)	
Nervous system disorders	Headache	30 (25.0)	10 (8.3)	
Respiratory, thoracic and mediastinal disorders	Cough	27 (22.5)	5 (4.2)	
Vascular disorders	Hypertension	27 (22.5)	7 (5.8)	
Skin and subcutaneous tissue disorders	Rash	23 (19.2)	3 (2.5)	
Gastrointestinal disorders	Vomiting	21 (17.5)	7 (5.8)	
Respiratory, thoracic and mediastinal disorders	Pneumonitis	9 (7.5)	2 (1.7)